Report of Foreign Issuer (6-k)
17 Novembre 2017 - 11:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of November 2017
Commission File Number: 001-36073
ENZYMOTEC LTD.
(Translation of registrants name into English)
Sagi 2000 Industrial Area
P.O. Box 6
Migdal HaEmeq 2310001, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
o
EXPLANATORY NOTE
Pursuant to the notice for the 2017 Annual and Extraordinary General Meeting of Shareholders (the
Meeting
) of Enzymotec Ltd. (the
Company
) that was published on November 2, 2017 and was attached as Exhibit 99.1 to the Companys Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission on November 2, 2017, the Company hereby furnishes the proxy statement and form of proxy card for the Meeting. The Meeting is scheduled to be held on Monday, December 11, 2017 at 5:00 p.m. (Israel time). Copies of the proxy statement and form of proxy card are
attached to this Form 6-K as Exhibits 99.1 and 99.2, respectively.
The information in this Form 6-K (including in Exhibits 99.1 and 99.2) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
Exchange Act
), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
ENZYMOTEC LTD.
|
Date: November 17, 2017
|
|
By:
/s/ Dror Israel
Name: Dror Israel
Title: Chief Financial Officer
|
ENZYMOTEC LTD. (NASDAQ:ENZY)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
ENZYMOTEC LTD. (NASDAQ:ENZY)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
Real-Time news about Enzymotec Ltd. - Ordinary Shares (delisted) (NASDAQ): 0 recent articles
Plus d'articles sur Enzymotec Ltd.